Literature DB >> 18080322

Noonan syndrome: psychological and psychiatric aspects.

Willem Verhoeven1, Ellen Wingbermühle, Jos Egger, Ineke Van der Burgt, Siegfried Tuinier.   

Abstract

Although Noonan syndrome (NS) is a disorder with a relatively high prevalence, virtually no information in adult patients is available about the psychological and psychopathological profile. In the present clinical report the first series of 10 NS patients from an ongoing project is presented. The purpose of the study is to investigate the psychopathology, social cognition and adaptation as well as the quality of life in NS patients aged 16 years or more. PTPN11 mutations were present in six patients and KRAS and SOS1 in one patient, respectively. In two patients no known mutation was found. The results demonstrate a variable level of intelligence and suggest moderately impaired social cognition in terms of emotion recognition and alexithymia. In some patients mild signs of anxiety and lowered mood are found that, however, do not meet the criteria for a specific psychiatric disorder. It is concluded that NS in adults is associated with a behavioral phenotype in which deficiencies in social and emotional recognition and expression may be key elements. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18080322     DOI: 10.1002/ajmg.a.32115

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Reduced recognition of dynamic facial emotional expressions and emotion-specific response bias in children with an autism spectrum disorder.

Authors:  Kris Evers; Jean Steyaert; Ilse Noens; Johan Wagemans
Journal:  J Autism Dev Disord       Date:  2015-06

3.  Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome.

Authors:  Elizabeth I Pierpont; Mary Ella Pierpont; Nancy J Mendelsohn; Amy E Roberts; Erica Tworog-Dube; Katherine A Rauen; Mark S Seidenberg
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

4.  Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome.

Authors:  Yong-Seok Lee; Dan Ehninger; Miou Zhou; Jun-Young Oh; Minkyung Kang; Chuljung Kwak; Hyun-Hee Ryu; Delana Butz; Toshiyuki Araki; Ying Cai; J Balaji; Yoshitake Sano; Christine I Nam; Hyong Kyu Kim; Bong-Kiun Kaang; Corinna Burger; Benjamin G Neel; Alcino J Silva
Journal:  Nat Neurosci       Date:  2014-11-10       Impact factor: 24.884

5.  Social cognitive training for adults with Noonan syndrome: a feasibility study.

Authors:  Renée L Roelofs; Ellen Wingbermühle; Roy P C Kessels; Jos I M Egger
Journal:  Neuropsychiatr Dis Treat       Date:  2019-02-26       Impact factor: 2.570

6.  Top-down or bottom-up: Contrasting perspectives on psychiatric diagnoses.

Authors:  Willem Ma Verhoeven; Siegfried Tuinier; Ineke van der Burgt
Journal:  Biologics       Date:  2008-09

Review 7.  Noonan syndrome.

Authors:  Amy E Roberts; Judith E Allanson; Marco Tartaglia; Bruce D Gelb
Journal:  Lancet       Date:  2013-01-10       Impact factor: 79.321

8.  PTPN11 Mutations in the Ras-MAPK Signaling Pathway Affect Human White Matter Microstructure.

Authors:  Mustafa Fattah; Mira M Raman; Allan L Reiss; Tamar Green
Journal:  Cereb Cortex       Date:  2021-02-05       Impact factor: 5.357

9.  Noonan syndrome with somnambulism: A rare case report.

Authors:  Samiksha Sahu; Suprakash Chaudhury; Daniel Saldanha
Journal:  Ind Psychiatry J       Date:  2021-03-15

10.  Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.

Authors:  Aaron D Levy; Xiao Xiao; Juliana E Shaw; Suma Priya Sudarsana Devi; Sara Marie Katrancha; Anton M Bennett; Charles A Greer; James R Howe; Kazuya Machida; Anthony J Koleske
Journal:  Cell Rep       Date:  2018-08-07       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.